# Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

> **NCT01941849** · PHASE1 · WITHDRAWN · sponsor: **University College, London**

## Conditions studied

- Phaeochromocytoma
- Paraganglioma

## Interventions

- **DRUG:** Vandetanib
- **RADIATION:** 131I-mIBG

## Key facts

- **NCT ID:** NCT01941849
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor patient accrual
- **Last updated:** 2015-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941849, "Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01941849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*